Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
|Poll|October 31, 2022
POLL: Have You Treated Generalized Pustular Psoriasis in Your Practice?
Author(s)Dermatology Times Staff
Click here to answer this week's poll.
Advertisement
Have You Treated Generalized Pustular Psoriasis in Your Practice?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Improving Early Identification and Escalation of HS
3
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
4
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
5